Track topics on Twitter Track topics that are important to you
Gene therapy company uniQure N.V. (NASDAQ:QURE) said CEO Daniel Soland resigned "due solely to personal family reasons." CFO Matthew Kapusta will be interim CEO, and will remain CFO. uniQure said it will not yet start a search for a permanent CEO while it adjusts its corporate strategy.
uniQure named Soland to the post in December 2015. uniQure shed $0.14 to $7.61 on Thursday. It announced the news after market close.
Original Article: uniQure CEO Soland resignsNEXT ARTICLE
Biological therapy involves the use of living organisms, substances derived from living organisms, or laboratory-produced versions of such substances to treat disease. Some biological therapies for cancer use vaccines or bacteria to stimulate the body&rs...